Brokerages forecast that CymaBay Therapeutics, Inc. (NASDAQ:CBAY) will post ($0.34) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for CymaBay Therapeutics’ earnings, with estimates ranging from ($0.38) to ($0.24). CymaBay Therapeutics reported earnings per share of ($0.23) during the same quarter last year, which indicates a negative year-over-year growth rate of 47.8%. The company is scheduled to report its next quarterly earnings results on Thursday, March 24th.
On average, analysts expect that CymaBay Therapeutics will report full year earnings of ($1.13) per share for the current year, with EPS estimates ranging from ($1.30) to ($0.61). For the next fiscal year, analysts forecast that the company will post earnings of ($1.34) per share, with EPS estimates ranging from ($1.74) to ($0.91). Zacks’ EPS averages are an average based on a survey of sell-side research firms that that provide coverage for CymaBay Therapeutics.
CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings data on Wednesday, November 10th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.07). During the same quarter in the prior year, the firm earned ($0.17) EPS.
NASDAQ CBAY traded up $0.04 during trading hours on Thursday, hitting $3.80. 388,381 shares of the company’s stock traded hands, compared to its average volume of 751,675. CymaBay Therapeutics has a 52-week low of $3.39 and a 52-week high of $7.77. The company has a market capitalization of $262.37 million, a PE ratio of -3.30 and a beta of 1.12. The company has a debt-to-equity ratio of 0.27, a current ratio of 10.18 and a quick ratio of 10.18. The firm’s 50-day moving average is $3.98 and its 200-day moving average is $4.11.
A number of institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp lifted its holdings in CymaBay Therapeutics by 3.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 249,796 shares of the biopharmaceutical company’s stock worth $911,000 after buying an additional 8,784 shares in the last quarter. BNP Paribas Arbitrage SA lifted its holdings in CymaBay Therapeutics by 99.9% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 13,884 shares of the biopharmaceutical company’s stock worth $51,000 after buying an additional 6,938 shares in the last quarter. Opaleye Management Inc. acquired a new stake in CymaBay Therapeutics during the 3rd quarter worth approximately $420,000. Metropolitan Life Insurance Co NY acquired a new stake in CymaBay Therapeutics during the 3rd quarter worth approximately $73,000. Finally, Commodore Capital LP lifted its holdings in CymaBay Therapeutics by 18.1% during the 3rd quarter. Commodore Capital LP now owns 4,169,896 shares of the biopharmaceutical company’s stock worth $15,220,000 after buying an additional 640,431 shares in the last quarter. Institutional investors own 74.97% of the company’s stock.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products pipeline include Seladelpar, MBX-2982, CB-0406, and CB-001. The company was founded on October 5, 1988 and is headquartered in Newark, CA.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.